Covid19 Clinical Trial
Official title:
Endocrine, Metabolic and Microbiome Influence on the Post-COVID Syndrome
NCT number | NCT04860869 |
Other study ID # | 20-0361 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 12, 2021 |
Est. completion date | May 31, 2022 |
Verified date | August 2022 |
Source | The University of Texas Medical Branch, Galveston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-COVID syndrome and patients that have recovered from COVID without lingering symptoms.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | COVID Non-Symptomatic controls (nPASC) Inclusion criteria 1. Male or female with a history of COVID with diagnosis confirmed by PCR test. 2. Minimum of 6 months since diagnosis of COVID by PCR test. 3. Ages 18 to 80 years. 4. Participant is willing and able to give informed consent for participation in the study. Exclusion criteria 1. Current COVID infection. 2. Unable to walk unassisted. 3. Significant heart, liver, kidney, blood or respiratory disease as determined by Principal Investigator. 4. Uncontrolled diabetes mellitus. 5. Any history of a recently (12 months) diagnosed cancer other than a skin cancer (excluding melanoma). 6. Current alcohol or drug abuse. 7. History of psychosis. 8. Pregnancy or become pregnant during the trial. 9. Subjects who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results. 10. Other medical condition or medication administration deemed exclusionary by the study investigators. COVID Symptomatic Subjects (PASC) Inclusion Criteria: 1. Male or female with a history of COVID with diagnosis confirmed by PCR test. 2. Has been seen at UTMB Post COVID clinic. 3. Minimum of 6 months since diagnosis of COVID by PCR test. 4. Ages 18 to 80 years. 5. Score of 3 or higher on any question 1-3 of the Brief Fatigue Inventory (BFI) questionnaire. 6. Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: 1. Current COVID infection. 2. Unable to walk unassisted. 3. Significant heart, liver, kidney, blood or respiratory disease. 4. Uncontrolled diabetes mellitus. 5. Any history of a recently (12 months) diagnosed cancer other than a skin cancer (excluding melanoma). 6. Current alcohol or drug abuse. 7. History of psychosis. 8. Pregnancy or become pregnant during the trial. 9. Subjects who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results. 10. Other medical condition or medication administration deemed exclusionary by the study investigators. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Medical Branch | Galveston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Medical Branch, Galveston |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin-Like Growth Factor-1 (IGF1) | Insulin-Like Growth Factor-1 (IGF1) will be measured in serum. Results will be reported in ng/mL. | baseline | |
Primary | Follicle Stimulating Hormone (FSH) | Follicle Stimulation Hormone (FSH) will be measured in serum. Results will be reported in IU/L. | baseline | |
Primary | Sex Hormone Binding Globulin (SHBG) | Sex Hormone Binding Globulin (SHBG) will be measured in serum. Results will be reported in nmol/L. | baseline | |
Primary | Total Testosterone | Total testosterone will be measured in serum of male subjects. Results will be reported in ng/dL. | baseline | |
Primary | Free Testosterone | Free testosterone will be measured in serum of male subjects. Results will be reported in pg/mL. | baseline | |
Primary | Prolactin | Prolactin will be measured in serum. Results will be reported in ng/mL. | baseline | |
Primary | Thyroid Stimulating Hormone (TSH) | Thyroid Stimulating Hormone (TSH) will be measured in serum. Results will be reported in mU/L. | baseline | |
Primary | C Reactive Protein (CRP) | C Reactive Protein (CRP) will be measured in serum. Results will be reported in mg/L. | baseline | |
Primary | Vitamin B12 | Vitamin B12 will be measured in serum. Results will be reported in pg/mL. | baseline | |
Primary | Vitamin D | Vitamin D will be measured in serum. Results will be reported in ng/mL. | baseline | |
Primary | Glucose tolerance as measured by the Oral Glucose Tolerance Test (OGTT) before glucose consumption | Glucose will be measured in serum before (0 minutes) oral consumption of 75g glucose. Glucose will be reported in mmol/L. OGTT will be performed on PASC subjects only. | Before glucose consumption | |
Primary | Glucose tolerance as measured by the Oral Glucose Tolerance Test (OGTT) 120 minutes after glucose consumption | Glucose will be measured in serum at 120 minutes after oral consumption of 75g glucose. Glucose will be reported in mmol/L. OGTT will be performed on PASC subjects only. | 120 minutes after glucose consumption | |
Primary | Insulin as measured by the Oral Glucose Tolerance Test (OGTT) before glucose consumption | Insulin will be measured in serum before (0 min) oral consumption of 75g glucose. Glucose will be reported in uIUl/L. OGTT will be performed on PASC subjects only. | Before glucose consumption | |
Primary | Insulin as measured by the Oral Glucose Tolerance Test (OGTT) 120 minutes after glucose consumption | Insulin will be measured in serum at 120 minutes after oral consumption of 75g glucose. Insulin will be reported in uIU/L. OGTT will be performed on PASC subjects only. | 120 minutes after glucose consumption | |
Primary | Glucose derived CO2 as measured by breath during the Oral Glucose Tolerance Test (OGTT) before glucose consumption | Glucose derived CO2 will be measured in breath samples before (0 min) oral consumption of 75g glucose isotopically labeled with 150 mg [U-13C6] glucose. Glucose-derived breath CO2 data are analyzed by measuring the ratios of 13CO2 to 12CO2 in single breath samples using an UBiT-IR300 infrared spectrophotometer (Otsuka Electronics, Hirakata, Osaka, Japan). The UBIT-IR300 calculates the difference in 13CO2 abundance from the baseline breath sample to each timed sample and expresses this as per mille delta over baseline (‰DOB). OGTT will be performed on PASC subjects only. |
Before glucose consumption | |
Primary | Glucose derived CO2 as measured by breath during the Oral Glucose Tolerance Test (OGTT) 120 minutes after glucose consumption | Glucose derived CO2 will be measured in breath samples at 120 minutes after oral consumption of 75g glucose isotopically labeled with 150 mg [U-13C6] glucose. Glucose-derived breath CO2 data are analyzed by measuring the ratios of 13CO2 to 12CO2 in single breath samples using an UBiT-IR300 infrared spectrophotometer (Otsuka Electronics, Hirakata, Osaka, Japan). The UBIT-IR300 calculates the difference in 13CO2 abundance from the baseline breath sample to each timed sample and expresses this as per mille delta over baseline (‰DOB). OGTT will be performed on PASC subjects only. |
120 minutes after glucose consumption | |
Primary | Characterization of fecal microbiome using molecular methods | Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for PCR. | baseline | |
Primary | Characterization of oral microbiome using molecular methods | Characterization of the oral microbiome using a commercially available sampling kit and our lab's patented array for PCR. Oral microbiome will be performed on PASC subjects only. |
baseline | |
Primary | Characterization of nasal microbiome using molecular methods | Characterization of the nasal microbiome using a nasal swab and our lab's patented array for polymerase chain reaction (PCR). Nasal microbiome will be performed on PASC subjects only. |
baseline | |
Primary | Mobility as measured by the EuroQOL-5 Dimensions | EuroQOL-5 Dimensions (EQ-5D) is a 5 item assessment of health status measuring mobility, self-care, usual activity, discomfort or pain and depression or anxiety. Mobility subscale is a range of 1-3, with a higher score indicating more dysfunction. |
baseline | |
Primary | Self-care as measured by the EuroQOL-5 Dimensions | EuroQOL-5 Dimensions (EQ-5D) is a 5 item assessment of health status measuring mobility, self-care, usual activity, discomfort or pain and depression or anxiety. Self-care subscale is a range of 1-3, with a higher score indicating more dysfunction. |
baseline | |
Primary | Usual Activity as measured by the EuroQOL-5 Dimensions | EuroQOL-5 Dimensions (EQ-5D) is a 5 item assessment of health status measuring mobility, self-care, usual activity, discomfort or pain and depression or anxiety. Usual Activity subscale is a range of 1-3, with a higher score indicating more dysfunction. |
baseline | |
Primary | Discomfort as measured by the EuroQOL-5 Dimensions | EuroQOL-5 Dimensions (EQ-5D) is a 5 item assessment of health status measuring mobility, self-care, usual activity, discomfort or pain and depression or anxiety. Discomfort subscale is a range of 1-3, with a higher score indicating more dysfunction. |
baseline | |
Primary | Depression/Anxiety as measured by the EuroQOL-5 Dimensions | EuroQOL-5 Dimensions (EQ-5D) is a 5 item assessment of health status measuring mobility, self-care, usual activity, discomfort or pain and depression or anxiety. Depression/Anxiety subscale is a range of 1-3, with a higher score indicating more dysfunction. |
baseline | |
Primary | Qualify of life as measured by Medical Outcome Study - Short Form 36 | Medical Outcome Study - Short Form 36 (MOS-SF-36) is a questionnaire that measures patient self-reported quality of life. Eight subscales are measured including physical function, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional wellbeing, social functioning, pain and general health. Scores for each subscale range from 0 - 100, with 100 being better perceived health and 0 being worst perceived health. | baseline | |
Primary | Anxiety as measured by the Hospital Anxiety and Depression Scale | Hospital Anxiety and Depression Scale (HADS) is a 14 item assessment which includes 7 questions for anxiety and 7 questions for depression, which are summed separately for a total score for each. HADS classifies scores 0-7 as normal; 8-10 as borderline abnormal (borderline case); 11-21 as abnormal case. | baseline | |
Primary | Depression as measured by the Hospital Anxiety and Depression Scale | Hospital Anxiety and Depression Scale (HADS) is a 14 item assessment which includes 7 questions for anxiety and 7 questions for depression, which are summed separately for a total score for each. HADS classifies scores 0-7 as normal; 8-10 as borderline abnormal (borderline case); 11-21 as abnormal case. | baseline | |
Primary | Distress is measured by the Impact of Event Scale | Impact of Event Scale - Revised (IES-R) is a 22-item self-report measure that assesses subjective distress caused by traumatic events. Respondents are asked to identify a specific stressful life event and then indicate how much they were distressed or bothered during the past seven days by each "difficulty" listed. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88) and subscale scores can also be calculated for the Intrusion, Avoidance, and Hyperarousal subscales. | baseline | |
Primary | Functional Status as measured by Activities of Daily Living | Activities of Daily Living (ADL) (Katz, 1970) is an index to assess functional status of basic activities of independent living. There are six functions measured, bathing, dressing, toileting, transferring, continence and feeding. Summary scores range from 0 (low function, severe functional impairment) to 6 (full function). | baseline | |
Primary | Independence measured by Instrumental Activities of Daily Living | Instrumental Activities of Daily Living (IADL) (Lawton, 1969) is an instrument to access independent living skills. These skills are considered more complex than the basic activities measured by the Katz ADL scale. There are eight categories, ability to use a telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances. Summary scores range from 0 (low function, dependent) to 8 (high function, independent). | baseline | |
Primary | Sleep Quality as measured by Pittsburgh Sleep Quality Index | Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1 month-time interval. Minimum Score = 0 (better); Maximum Score = 21 (worse). Interpretation: Total < 5 associated with good sleep quality. Total > 5 associated with poor sleep quality. | baseline | |
Primary | Strength as measured by using hand grip dynamometry | Maximum strength will be measured using a hand grip dynamometer. | baseline | |
Primary | Growth hormone as measured by Glucagon Stimulation Test before glucagon administration | Growth hormone secretion will be measured using the glucagon stimulation test. Serum will be collected for the baseline (time: 0 minutes) to test for levels of human growth hormone. 1 mg glucagon (for subjects over 90 kg, 1.5 mg glucagon) will be injected intramuscularly (IM) in the deltoid muscle of the subject and blood will be drawn at specified time points. Results will be reported as ng/mL. |
Before glucagon administration | |
Primary | Growth hormone as measured by Glucagon Stimulation Test 90 minutes after glucagon administration | Growth hormone secretion will be measured using the glucagon stimulation test. Serum will be collected at time point 90 minutes after glucagon injection to test for levels of human growth hormone. Results will be reported as ng/mL. |
90 minutes after glucagon administration | |
Primary | Growth hormone as measured by Glucagon Stimulation Test 120 minutes after glucagon administration | Growth hormone secretion will be measured using the glucagon stimulation test. Serum will be collected at timepoint 120 minutes after glucagon injection to test for levels of growth hormone. Results will be reported as ng/mL. |
120 minutes after glucagon administration | |
Primary | Growth hormone as measured by Glucagon Stimulation Test 150 minutes after glucagon administration | Growth hormone secretion will be measured using the glucagon stimulation test. Serum will be collected at timepoint 150 minutes after glucagon injection to test for levels of growth hormone. Results will be reported as ng/mL. |
150 minutes after glucagon administration | |
Primary | Growth hormone as measured by Glucagon Stimulation Test 180 minutes after glucagon administration | Growth hormone secretion will be measured using the glucagon stimulation test. Serum will be collected at timepoint 180 minutes after glucagon injection to test for levels of growth hormone. Results will be reported as ng/mL. |
180 minutes after glucagon administration | |
Primary | Basal Metabolic rate as measured by Resting Energy Expenditure | Resting Energy Expenditure will be measured by capturing the expired breath of subjects while at rest with a metabolic cart over a 30 minute time period. Data from the first 5 minutes will be discarded and the remaining 25 minutes of data will be averaged to calculate the resting energy expenditure. Data will be reported as kilocalories/day Procedure will be performed on PASC subjects only. |
baseline | |
Primary | Cortisol as measured by the adrenocorticotropic hormone stimulation test (ACTH) before cortrosyn administration | Cortisol secretion will be measured using the ACTH stimulation test. Serum will be collected for the baseline (time: 0 minutes) to test for levels of cortisol. 0.25 mg Cortrosyn will be administered and additional serum (3.5 mL) will be collected at specified time points. Results will be reported as ug/dL. Procedure will be performed on PASC subjects only. |
Before Cortrosyn administration | |
Primary | Cortisol as measured by the adrenocorticotropic hormone stimulation test (ACTH) 30 minutes after cortrosyn administration | Cortisol secretion will be measured using the ACTH stimulation test. Serum will be collected at time point 30 minutes after Cortrosyn administration to test for levels of cortisol. Procedure will be performed on PASC subjects only. Results will be reported as ug/dL. |
30 minutes after Cortrosyn administration | |
Primary | Cortisol as measured by the adrenocorticotropic hormone stimulation test (ACTH) 60 minutes after cortrosyn administration | Cortisol secretion will be measured using the ACTH stimulation test. Serum will be collected at time point 60 minutes after Cortrosyn administration to test for levels of cortisol. Results will be reported as ug/dL. Procedure will be performed on PASC subjects only. |
60 minutes after Cortrosyn administration | |
Primary | Cognitive Function as measured by Montreal Cognitive Assessment | The Montreal Cognitive Assessment (MoCA) will be used to assess cognition. The Montreal Cognitive Assessment (MoCA) is a rapid assessment of cognition. The MoCA consists of 9 questions with the following subcategories: visuospatial/executive, naming, memory, language, abstraction, delayed recall and orientation. The MoCA has been used extensively to detect cognitive impairment in many conditions, including head trauma. Version 7.1 will be used. Scores range from 0 to 30, higher score being a better outcome. |
baseline | |
Primary | Walking as measured by 6 minute walk test | Walking performance will be assessed in subjects during 6 minutes of walking in long corridor hallways. This is a standard test of walking performance that has been validated in similar studies. Subjects will be asked to walk at a 100% effort. Results will be reported as total distance traveled in meters (m). Procedure will be performed on PASC subjects only. | baseline | |
Primary | Fatigue as measured by the Multidimensional Fatigue Symptom Inventory | Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue. There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score. The range of the total score is -24 to 96, with the higher the number meaning more fatigue. |
baseline | |
Primary | Symptoms of Growth Hormone Deficiency measured by the questionnaire Quality of Life - Assessment of Growth Hormone Deficiency in Adults | Symptoms of growth hormone deficiency will be measured using the Quality of Life - Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). This 25-item questionnaire measures specific symptoms associated with growth hormone deficiency, with a score range of 0 to 25, with a higher score indicating worse symptoms. | baseline | |
Primary | Depression measured by the Beck Depression Inventory-II | The Beck Depression Inventory- II (BDI-II) assesses depressive symptom severity. The BDI-II is comprised of 21 individual items reflecting specific cognitive, affective, and physical symptoms of depression. Each item includes four statements that vary in the description of symptom of severity. Scores range from 0 to 3, with a score of "3" indicating a severe symptoms and a score of "0" indicating an absence of concern with that particular aspect of depressive symptomology. The total score is the sum of all endorsed statements. The maximum total score is 63. The BDI-II Manual designates the following raw score classifications depression severity: =13 = minimal; 14-19 = mild; 20-28 = moderate; = 29 = severe. | baseline | |
Primary | Gastrointestinal Health measured by the Gastrointestinal Symptom Rating Scale | The Gastrointestinal Symptom Rating Scale (GSRS) is a specific 15-item questionnaire. Subjects are asked to numerically score their subjective symptoms on a scale of 1-7 (1 = no discomfort at all; 7 = very severe discomfort) . The sum of the scores for all 15 items is regarded as the GSRS total score. Total scores range from 15 (best outcome) to 105 (worst outcome). | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |